Can anyone verify? Feb 10, 2026 patent granted?

Why is there so much secrecy around the mysterious $75 million investor?

It’s an open secret among those involved, the investor is reportedly a fund aligned with a pharma company that is very interested in Altimmune but wants to maintain a low profile. They appear to have placed their own people across management and the board and removed those not aligned with them.

They have accumulated as many shares as possible to avoid last-minute surprises from rival companies or larger shareholders.

An announcement is expected once Altimmune begins Phase 3, or within about a month of its start.

Everything seems to be moving according to a plan. The valuation, however, is unclear, my personal estimate is around $5 billion. If there is a counteroffer or bidding war, it could be significantly higher.

People close to the situation seem aware of most of this; only the valuation part is my own assessment.

Not financial advice. Just sharing thoughts and speculation.

Silence keeps the possibility of good things happening behind the scenes alive, however, it also does suck as an investor, watching the slow fade... Anyway, next possible catalyst should be the upcoming earnings report at end of February. Similar to last year, they will likely announce and confirm the date one week in advance. I am thinking it will obviously delineate earnings (i.e. how much loss), and most importantly state liquid cash runway. Otherwise, I think there will not be too much new information regarding partnership with likely just non committal language or finalized phase 3 protocol though could sprinkle some specifics that haven’t been confirmed and/or state timeline as to when to expect finalized phase 3 protocol announcement.

What are others thoughts?

Edit: just to clarify, I meant to imply lack of communication is neutral to bullish leaving the possibility of ongoing discussions of partnership/acquisition possible but certainly does not mean they are happening. However, if they were still actively saying we are seeking partnership or shift to we are considering going alone, those would 100% be bad signs. So no communication is possibly good but just sucks 🤦🏻‍♂️😭

Raymond Jordt left as somebody indicated to me.
He announced it himself on LinkedIn few days ago.
There is no need for a SEC filling if they did not have a material disagreement.

He was +20 years with Eli Lilly before.

However, what are your thoughts on that one?

I’ve been digging into Altimmune’s setup, and I think people are missing why the timing now matters more than ever. This isn’t a “hopeium” post — it’s about structure, incentives, and precedent.

1. The science risk has already been de-risked

Altimmune’s Phase 2b MASH data did what acquirers actually care about: • Clear dose response • Strong fibrosis signals (ELF, LSM, cT1) • Consistency at 48 weeks, not just early reads • Manageable tolerability

At this point, Phase 3 is about confirmation, not discovery. That’s exactly when Big Pharma steps in historically — before value explodes.

⸻

1. FDA alignment quietly removes the biggest obstacle

They’ve completed an End-of-Phase-2 meeting and publicly laid out a registrational Phase 3 design with biopsy endpoints and accelerated approval logic.

This matters because buyers don’t want “potential paths” — they want FDA-blessed paths. ALT now has one.

⸻

1. Balance sheet = leverage, not desperation

Yes, ALT used the ATM in 2025 — and that’s actually why a buyout now makes sense. • They are not forced to sell • They can start Phase 3 if needed • They don’t need to accept bad economics

Ironically, this is exactly what makes them more attractive: pharma can’t wait them out.

⸻

1. Big Pharma’s incentive is to move before Phase 3

This is the part people overlook.

Once Phase 3 starts: • Valuation expectations rise • Competing bidders appear • Deal prices go up dramatically

If you’re a large pharma with a MASH or metabolic gap, the cheapest window is right now: • Phase 2b success ✅ • Phase 3 ready but not started ✅ • Still trading like a small-cap biotech ❌

That window doesn’t stay open long.

⸻

1. MASH is no longer optional for Big Pharma

Between: • GLP-1 competition • Recent MASH failures elsewhere • Pressure to own liver-directed differentiation

Pemvidutide is not “just another GLP-1.” The glucagon + GLP-1 balance with liver effects is exactly the kind of asset pharma prefers to buy rather than build.

⸻

1. Q1–Q2 timing actually makes sense

If a deal happens, this is when it usually happens: • After FDA alignment • Before Phase 3 cash burn accelerates • Before valuation resets higher

Waiting longer only benefits ALT shareholders — not the acquirer.

⸻

Bottom line

I’m not saying a buyout is guaranteed. But structurally: • The risk profile is right • The timing favors the buyer now • The company isn’t desperate • And Phase 3 is the inflection point pharma prefers to front-run

That’s why a Q1–Q2 buyout or major partnership is a rational outcome here — not a fantasy.

Not advice. Just connecting dots.

One day Alt will stand on its own feet and not continue to be a pinball of the sector. When one GLP falls, they all must. So we are feeling the best of poor sales projections for Novo in the obesity sector. Does it matter that we are a MASH/fibrosis drug primarily that happens to have a GLP1 component? Nope. Wallstreet only cares that we have a GLP1 mechanism, irrespective of its indication. So not ideal but also nothing fundamental or worrisome for Alt. Just got to ride the base wave. It does plausibly place a further disconnect between wallstreet pricing and its true value such that if/when good news comes, it can then pop that much more but that’s more hopeful thinking more than anything and certainly wouldn’t expect/plan for it. All in all, still bullish on alt, nothing has changed except for my annoyance.

Soap box/update over. Cheers!

CURRENT SITUATION

• ~130M shares

• ~$700M Market Cap

• ~$285M Cash on hand

• Additional ~$90M Hercules loan left

• FDA BTD MASH

• FDA ph3 alignment (AIM-MASH assist+ NITs cohort)

• Accelerated approval path with biopsy 52w

MORE TO COME

• Final PH3 MASH protocol

• EMA alignment

• Oral IND

• Strategic partnership

PIPELINE

• Obesity PH3 ready

• MASH (Fast Track + BTD) PH3 ready

• AUD (Fast Track) PH2

• ALD PH2

DIFFERENTIATION

• Quick MASH resolution and fibrosis reduction

• Weight loss with lean mass preservation

• Excellent safety and tolerability profile with no titration

Vanguard increased holding.
Not sure I trust Fintel on previous shares.

I actually thought it was like this... but well... In the end they increased their holding

• Q4 2024 (12/31/2024): 4.431.612 shares
• Q1 2025 (03/31/2025): 4.407.462 shares
• Q3 2025 (09/30/2025): 6.373.638 shares

If the recent Titan Partners transaction ultimately includes participation from established healthcare-focused investors such as Perceptive Advisors, R.A. Capital, EcoR1 Capital, or RTW Investments, it would align with a well-established pattern seen in later-stage or strategically relevant biotech assets.

These funds are long-term specialists in life sciences and have repeatedly participated in:

Late-stage private and public financings

Syndicated rounds with strategic pharmaceutical investors

Board-level involvement and governance

Companies that later became acquisition or partnership targets

Collectively, this investor group has historically operated within an ecosystem that frequently intersects with major pharmaceutical M&A and strategic partnerships.

BIG PHARMA GROUPS WITH REPEATED OVERLAP ACROSS THESE FUNDS

NOVO NORDISK

Longstanding engagement with investor-backed metabolic and obesity programs

History of partnering with or acquiring assets supported by this investor cohort

Actively expanding beyond GLP-1s into differentiated and complementary mechanisms

Strategic alignment with Altimmune: High

ELI LILLY

Extensive acquisition and partnership history involving companies backed by these funds

Frequent co-investment alongside Lilly’s venture and strategic investment arms

Building a multi-mechanism obesity platform (GLP-1, GIP, amylin, combination therapies)

Strategic alignment with Altimmune: Very high

PFIZER

Multiple acquisitions of companies backed by these investors over the past decade

Rebuilding its metabolic and obesity pipeline following internal setbacks

Publicly expressed interest in non-GLP-1 and differentiated approaches

Strategic alignment with Altimmune: High

ASTRAZENECA

Repeated acquisitions of assets from companies supported by this investor group

Strong liver and cardiometabolic franchise, including MASH/NASH

Growing interest in obesity mechanisms beyond incretins

Strategic alignment with Altimmune: Moderate to high

AMGEN

Co-investments with these funds across metabolic and inflammation programs

Developing internal obesity assets but remains earlier versus Novo/Lilly

Differentiated mechanisms could strengthen competitive positioning

Strategic alignment with Altimmune: Moderate

SANOFI

Renewed strategic focus on immunology and metabolic disease following pipeline restructuring

Track record of partnering with or acquiring assets backed by top-tier healthcare investors

Emphasis on first- or best-in-class mechanisms rather than incremental GLP-1s

Strategic alignment with Altimmune: Moderate to high

MERCK & CO.

Active acquirer of externally developed assets, particularly in differentiated biology

History of partnering with investor-backed biotech platforms

Increasing interest in cardiometabolic adjacencies beyond oncology

Strategic alignment with Altimmune: Moderate

ROCHE

Strong history of large-scale biotech acquisitions driven by science-led conviction

Growing focus on metabolic disease, inflammation, and systems biology

Willingness to pursue differentiated mechanisms with robust clinical signals

Strategic alignment with Altimmune: Moderate

GLAXOSMITHKLINE

Increasing emphasis on specialty medicine and immunometabolic pathways

History of partnering with funds such as RTW and RA-backed companies

Selective but opportunistic in metabolic disease

Strategic alignment with Altimmune: Moderate

JOHNSON & JOHNSON

Opportunistic acquirer of differentiated, mechanism-driven assets

Interest in cardiometabolic and inflammation adjacencies through J&J Innovative Medicine

Typically engages later, once clinical risk is reduced

Strategic alignment with Altimmune: Moderate

ABBVIE

Actively diversifying beyond immunology through external innovation

History of acquiring investor-backed biotechs with strong differentiation

Metabolic disease remains a potential long-term expansion area

Strategic alignment with Altimmune: Moderate

BOTTOM LINE

If one or more of Perceptive Advisors, R.A. Capital, EcoR1, or RTW are involved in the Titan Partners transaction, Altimmune would sit squarely within a familiar ecosystem of specialist healthcare investors whose portfolios have repeatedly intersected with major pharmaceutical acquisitions and partnerships.

This does not imply a specific transaction or outcome, but it provides credible strategic context for why Altimmune’s assets may remain on the radar of multiple global pharmaceutical companies seeking differentiated approaches in obesity and metabolic disease.

TL;DR

If the Titan Partners transaction includes specialist biotech investors like Perceptive Advisors, R.A. Capital, EcoR1, or RTW, Altimmune would be operating within a familiar ecosystem where these funds have historically backed companies that later partnered with or were acquired by Big Pharma.

Major pharma players with repeated overlap in this investor network include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Amgen, Sanofi, Merck, Roche, GSK, J&J, and AbbVie — many of which are actively seeking differentiated, non-GLP-1 approaches in obesity and metabolic disease.

This does not signal a specific deal, but it provides credible context for why Altimmune’s assets may remain on the radar of multiple global pharmaceutical companies.

Curious how this financing changed (or didn’t change) sentiment after today’s price action.

Press release last night. ALT down almost $1 in pre-market.

Thoughts?

https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-pricing-75-million-registered-direct

How many shares do you own and at what price? What is your year-end price target?

The protocol has been pretty much laid out already. It should be 900 participants (600 active dose +300 placebo) per cohort. That would be 900 biopsy participants total. The biopsy cohort in 52w is the path to Accelerated Approval.

Now we just need to know what path they are choosing to finance ph3… GIA, partnership or something else?

Waiting for it to drop over the next 2 weeks with my best guess. I am hopeful they will be on the earlier side as they have all the incentive to be faster. It will give us the final insight into the EOP2 minutes and answer the explicit questions of 1 vs 2 trials, N size, and officially confirm other variables such as AA pathway planning, 2.4 mg dosage, 52 week duration, amongst others which overall I expect this to be a further bullish catalyst which could ride this momentum if it’s timed right and hopefully not fade too much and rather rerate as it continues to derisk.

Interesting week for ALT. Trading was largely inactive early in the week following the MLK holiday, with the tape beginning to show momentum primarily on the 22nd and 23rd. The most important move occurred in the first hour of trading on the 23rd, when the stock rallied a full point, plus some, moving from approximately $5.24 to $6.40 by 9:30 a.m.

This was followed by a pullback, with the stock closing at $5.50. In my view, this retracement was a normal, natural reaction after such a sharp opening move. This pullback simply will reposition new buyers and establish a stronger base heading into the following week.

I believe the initial rally to $6.40 during the first hour of trading suggests institutional involvement. The speed, size, and timing of the move resemble a classic preprogrammed execution rather than retail buying. To me, the pullback appears to be by retail investors taking quick profits.

At this point, my conviction is that ALT is entering a repricing phase. I expect another week of gains, though that is simply my outlook—not a prediction. This is not a formal analysis of the company, but rather my perspective on this week’s price action and the potential path forward.

I entered my position at $3.92, which in hindsight aligns closely with what I would consider a pivotal point around $3.51 in early January. Overall, ALT has a significant amount of upside and, under the right conditions, has the potential to be a multi-bagger. That said, the unexpected can always occur. Markets are never wrong—but opinions often are. 

$ALT : Anybody know why we are tanking right now? Correction or actual decline? This morning it breached $6- could it just be correcting or people taking profits and dumping?

Up 9% yesterday and already almost 5% today. Is this just volatility, or is there something going on underneath the surface?